Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 2Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

pembrolizumab 12Gemcitabine 9Cetuximab 7Psychiatric Rehabilitation 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Fluorouracil 6Early Intervention, Educational 6Cisplatin 6cediranib 5Leucovorin 5Carboplatin 5sargramostim 4Standard of Care 4Oxaliplatin 4Methods 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4selpercatinib 3aldesleukin 3adagrasib 3Trastuzumab 3Therapeutics 3Pemetrexed 3Nivolumab 3Irinotecan 3Fluorodeoxyglucose F18 3Bortezomib 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Dacarbazine × Thoracic × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡